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Vitamin A has both positive and negative regulatory functions in the immune system. While vitamin A is required for normal
formationofimmunecellsandepithelialcellbarriers,vitaminAdeﬁciencycanleadtoincreasedinﬂammatoryresponsesandtissue
damage. The mechanism with which vitamin A and its metabolites such as retinoids negatively regulate inﬂammatory responses
hasnotbeenclearlydeﬁned.Recently,ithasbeenestablishedthatretinoidspromotethegenerationofimmune-suppressiveFoxP3+
regulatory T cells while they suppress the T cell diﬀerentiation into inﬂammatory Th17 cells in the periphery such as intestine.
These novel functions of retinoids provide a potentially important immune regulatory mechanism. In this review, we discuss the
functions of retinoids in the development of the FoxP3+ cells and Th17 cells, the phenotype and functions of retinoid-induced
FoxP3+ T cells, and the impact of retinoid-induced FoxP3+ T cells on the immune tolerance.
Copyright © 2008 Chang H. Kim. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. INTRODUCTION
The immune system is regulated by various types of cells
and the factors that are produced by these cells. The cells
of the immune system sense the presence of the antigens
and other signals, generated from pathogens and commen-
sals, and respond to the stimuli in positive or negative ways.
Among the immune cells, CD4+ T cells play central roles in
regulation of immune responses by activating or suppress-
ing immune cells and tissue cells. Na¨ ıve CD4+ T cells, pro-
duced in the thymus, can become Th1, Th2, or Th17 cells
[1–5],whichactaseﬀectorcellstostimulatetheimmunesys-
tem to clear pathogens and tumor cells. On the other hand,
regulatory T cells, exempliﬁed by FoxP3+ T cells, suppress
the immune system to prevent overactive responses and in-
ﬂammation induced by T cells and their downstream (non-
T) eﬀector cells [6–11]. Humans and mice that do not have
functional FoxP3+ T cells as the result of mutations in the
FoxP3 gene suﬀer from inﬂammatory and autoimmune dis-
eases and die young [12–16], which serves as the evidence
for the essential roles of these T cells in maintaining immune
tolerance. FoxP3+ T cells are made in the thymus from T cell
progenitors and in the periphery from na¨ ıve CD4+ T cells.
Na¨ ıve FoxP3+ T cells, made in the thymus, exclusively mi-
grateto secondarylymphoid tissuesforactivation and diﬀer-
entiation into memory type FoxP3+ T cells that can migrate
to B cellsites,nonlymphoid tissues, or sites ofTh1 or Th2 in-
ﬂammation [11, 17–19]. A number of factors in the periph-
ery can regulate the generation or diﬀerentiation of FoxP3+
T cells. These are antigens, antigen-presenting cells such as
dendritic cells, cytokines, and tissue-speciﬁc factors that are
producedinthecellsofcertaintissuesites.Onegroupofsuch
tissue-speciﬁcfactorsareretinoids,whichcaninduceFoxP3+
T cells with a gut-speciﬁc tissue tropism from na¨ ıve FoxP3−
T cells [20–26]. Reciprocally, retinoids suppress the genera-
tion of inﬂammatory Th17 cells. We will discuss in this re-
view the general properties and functions of retinoids, their
r o l e si nr e g u l a t i o no fTc e l ld i ﬀerentiation, and the impact of
this process on regulation of the immune system.
2. SYNTHESIS, RECEPTORS, AND BIOLOGICAL
FUNCTIONS OF RETINOIDS
Preformed vitamin A in food digesta is absorbed in the form
of retinol, which can be made into retinal and retinoic acid
(RA) [27]( Figure 1). Also retinol can be generated from2 Clinical and Developmental Immunology
provitamin A carotenoids such as betacarotene [28–31].
Plasma retinol binding proteins and cellular retinol binding
proteins transport and stabilize retinol [32]. Some antigen-
presenting cells in gut-associated lymphoid tissues have a
unique feature, which is the ability to produce retinoic acid
from vitamin A [33]( Figure 1). The conversion of retinol
(vitamin A) to retinal is catalyzed by a subfamily of al-
cohol dehydrogenases (ADH), and the subsequent conver-
sion of retinal to RA is catalyzed by retinal dehydroge-
nases (RALDH) [34]. While ADH5 is ubiquitously expressed
by dendritic cells isolated from all of the secondary lym-
phoid organs, the ADH1 and ADH4 isoenzymes are pref-
erentially expressed by only gut-associated lymphoid tissue
(GALT) dendritic cells. Peyer’s patch dendritic cells express
RALDH1, while mesenteric lymph node dendritic cells ex-
press RALDH2 [33]. The retinoic acid, produced by GALT
dendritic cells, induces T cell expression of the two gut hom-
ing receptors CCR9 and α4β7[ 33]. CCR9 is the chemokine
receptor for TECK/CCL25, which is expressed in the small
intestine [35], and α4β7a c t sa sa na d h e s i o nm o l e c u l ef o r
lymphocyte rolling and ﬁrm adhesion on the surface of mu-
cosal endothelial cells by binding to its ligand mucosal ad-
dressin cell adhesion molecule (MAdCAM-1) [36, 37].
Among the metabolites of vitamin A, 11-cis-retinal, all-
trans-retinoic acid (At-RA) and 9-cis-RA mediate the ma-
jor biological functions of the vitamin [29, 34]. Vitamin A
has pleiotropic functions in the body. 11-cis-retinal func-
tions as chromophores in light absorption for vision, and
retinoic acid participates in bone formation, reproduction,
and diﬀerentiation of many cell types during embryogenesis
[28–30]. In this regard, retinoid deﬁciency or overdoses can
cause teratogenesis [38]. Vitamin A plays important roles in
theimmune system.Onesuchafunctionis itsroleinthefor-
mation of epithelial linings of the body including eyes, mem-
branes of mucosal tissues in the respiratory, urinary and in-
testinal tracts, and skin, which serve as barriers to prevent
the invasion by pathogens [39]. Through their eﬀects on cell
diﬀerentiation and death, retinoids inhibit or reverse the car-
cinogenic process in some types of cancers in oral cavity,
head and neck, breast, skin, liver, and blood cells [40, 41].
At-RA and 9-cis-RA are the ligands for retinoid nuclear
receptorsthatactastranscriptionfactorsforgeneexpression.
As retinoid nuclear receptors, RA receptor (RAR) isotypes
(α, β,a n dγ) and the retinoid X receptor (RXR) isotypes (α,
β,a n dγ) have been identiﬁed [29]. Each receptor has mul-
tiple isoforms, generated through alternative mRNA splic-
ing and/or transcription [30, 31]. At-RA preferentially binds
RARs, whereas 9-cis-RA binds equally well to both RARs
and RXRs [29, 42]. The two groups of retinoid nuclear re-
ceptors form RXR/RAR heterodimers, which can function as
either transcriptional repressors or activators depending on
the availability and type of retinoid ligands [43]. In the ab-
sence of RAR ligands, aporeceptors recruit corepressors such
as nuclear receptor corepressor (N-CoR) or silencing me-
diator for retinoid and thyroid hormone receptor (SMRT),
which then recruit histone deacetylases (HDACs). Binding
of RAR agonists to the receptors induces active conforma-
tion of the receptors (Figure 2). This decreases the aﬃnity
for corepressors and creates a binding surface for histone
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Figure 1: Synthesis of retinoic acid in the dendritic cells of the in-
testine. Vitamin A is consumed as retinyl ester and hydrolyzed by
retinyl ester hydrolase (REH). Retinol, entered into cells, is oxi-
dized to retinaldehyde by alcohol dehydrogenase (ADH) or short-
chain dehydrogenase/reductase (SDR). The reverse reaction is me-
diated by aldo-keto reductase (AKR) or SDR. Retinaldehyde can
be converted to retinoic acid (all-trans retinoic acid or At-RA) by
retinaldehyde dehydrogenase (RALDH). Retinoic acid is degraded
in cells by cytochrome P450 (CYP26). It is known that dendritic
cells in the gut-associated lymphoid tissues (GALT) such as Peyer’s
patches and MLN express high levels of ADH1, ADH4, RALDH1,
and/or RALDH2. The retinoic acid produced by dendritic cells can
be exported for other cells such as T cells during the cognate inter-
action between dendritic cells and T cells.
acetyltransferase (HAT) coactivators, such as CREB-binding
protein (CBP) and p160 (e.g., TIF2). Transcriptional coac-
tivators are involved in chromatin remodeling (decondensa-
tion due to histone acetylation) or recruitment of the basal
transcription machinery. RXR agonists alone cannot disso-
ciate the corepressors from heterodimers of RAR-RXR, and
retinoid receptor antagonists would prevent the formation
of the holoconformation. Please see the reviews [44, 45]f o r
more details on retinoid receptor-mediated gene expression.
Many functions of retinoids have been identiﬁed in reg-
ulation of immune responses. As positive roles in regulation
of the immune system, retinoids enhance the numbers and
eﬀector functions of neutrophils, NK cells, B cells, and Th2
cells [28, 46–52]. Retinoids induce the gut homing recep-
tor expression in T and B cells [19, 33, 53–55]a n dBc e l lI g
switch to IgA [51, 55], and, therefore, are important regu-
lators of mucosal immunity. Vitamin A is required for an-
tibody responses to T-dependent and bacterial polysaccha-
ride antigens [56, 57], normal IgA levels in the intestinal
ﬂuid [58], prevention of activation-induced T cell apopto-
sis [59, 60], and normal phagocytic functions and resistance
to bacterial pathogens [61]. Vitamin A supplementation canChang H. Kim 3
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Figure 2: Control of gene expression by retinoic acid. RAR-RXR het-
erodimers serve as the nuclear receptors for retinoic acid. When
RAR ligands (e.g., At-RA) are not available, the RAR-RXR het-
erodimersattractcorepressorsandhistoneacetyldeacetylasestothe
geneswhichareunderthecontrolofretinoicacidresponseelements
(RARE: direct repeats of AGGTCA with a 5-bp spacer; also called
DR-5), resulting in a closed conformation of the chromosome and
blocked transcription. When RAR ligands are available in a tissue
microenvironment (e.g., produced from dendritic cells in the in-
testine), they would enter into T cells and activate RAR-RXR het-
erodimers. This is followed by the release of corepressors and at-
traction of coactivators, which, in turn, recruit histone acetyl trans-
ferases, resulting in an open conformation of the chromosome and
transcription of the genes. In this regard, the human and mouse
FoxP3 promoters have several RARE’s and become acetylated at hi-
stones in response to retinoic acid.
decrease serum concentrations of inﬂammatory cytokines
such as TNF-α and IL-1 but increase suppressive cytokines
such as IL-10 [42, 62]. In this regard, supplementation
with vitamin A can suppress inﬂammation in experimen-
tal autoimmune encephalomyelitis [47, 63–66]. Paradoxi-
cally, vitamin A deﬁciency is linked to both defective delayed
type hypersensitivity [67–69] and excessive Th1 cell func-
tion [46–50, 70, 71]. Vitamin A is also linked to both lower
and higher incidences of several types of cancers in humans
[72, 73].
Retinoids are being used to treat acne, psoriasis, and
selected cancer types. The mechanisms of action for the
retinoids in treatment of psoriasis and acne are poorly elu-
cidated [74, 75]. The skin cells can be the direct therapeu-
tic target for retinoids. It is equally possible that the ther-
apeutic eﬀect of retinoids can be indirect though regula-
tion of the immune system that mediates inﬂammation in
the skin. Additionally, retinoids have therapeutic eﬀects on
acute promyelocytic leukemia (APL) cells and AIDS-related
Kaposi’s sarcoma cells by regulating cellular diﬀerentiation
and/or proliferation [76, 77]. APL is a speciﬁc form of mye-
locytic leukemia characterized by the t(15;17) chromosomal
translocationandformationoftheabnormalPML-RARαfu-
sion protein [78, 79]. Retinoic acid, when administered at
pharmacological doses, can induce leukemic cell diﬀerentia-
tion and cell-cycle arrest by reversing the dominant-negative
eﬀects of PML-RARα fusion protein on the functions of the
wild-type PML and RARα proteins [41, 80, 81].
3. REGULATION OF THE FoxP3+ TC E L L
GENERATION BY RETINOIDS
FoxP3+ T cells are regulatory T cells that can suppress im-
mune responses. FoxP3+ Tc e l l sa r em a d el a r g e l yi nt w od i f -
ferentways:theyaremadeinthethymusfromTcellprogeni-
tors or they can be made fromFoxP3− na¨ ıveTcellsinthepe-
riphery during their activation with antigen-presenting cells
such as dendritic cells. In the periphery, many factors can af-
fect the generation of FoxP3+ Tc e l l sf r o mn a ¨ ıve T cells. One
of the factors is the route of antigen administration. Immu-
nization through the oral route has the tendency to induce
FoxP3+ T cells [82, 83]. Another factor is the cytokine mi-
lieu. TGF-β1i sav e r ye ﬀective cytokine that induces FoxP3+
Tc e l l sf r o mn a ¨ ıve T cells [84]. In this regard, the induc-
tion of FoxP3+ T cells by mucosal immunization is depen-
dent on TGF-β1[ 82, 83]. Another cytokine, IL-2, is impor-
tant for peripheral induction and maintenance of FoxP3+ T
cells [85–88]. IL-2 signaling is dispensable for the induction
ofFoxP3+ Tcellsinthethymusbutrequiredformaintenance
of FoxP3+ T cells in the periphery [87, 89]. It is not just a co-
incidence that FoxP3+ T cells highly express CD25 (the alpha
chain of the heterotrimeric high-aﬃnity IL-2 receptor) to re-
ceive the IL-2 signal. Another factor is the type of antigen-
presenting cells. Both monocyte-derived dendritic cells and
plasmacytoid dendritic cells can induce CD4+ CD25+ Tc e l l s
or FoxP3+ T cells [90–92]. Dendritic cells in tumors are par-
ticularly eﬃcient in inducing FoxP3+ T cells [93], which pro-
videsanexplanationforthehighprevalenceofFoxP3+ Tcells
in many types oftumors. Yet anotherfactoris the presence of
certainpathogensortoll-likereceptor(TLR)ligands[94,95].
TLR ligands can either expand FoxP3+ T cells or suppress
their generation and functions [96, 97]. The FoxP3+ Tc e l l
expansion by dendritic cells can be augmented in the pres-
ence of TLR ligands such as LPS [98].
Recently, a number of groups including our group re-
ported that retinoic acid regulates the peripheral induction
of FoxP3+ CD4+ T cells [20–26]. Retinoic acid, together with
TGF-β1, induces not only CD4+ but also CD8+ FoxP3+ T
cells [20]. As mentioned before, the dendritic cells in gut-
associated lymphoid tissues have the capacity to provide
retinoic acid to T cells undergoing antigen priming [33].
While splenic dendritic cells could not induce FoxP3+ T
cells from na¨ ıve T cells, the dendritic cells isolated from4 Clinical and Developmental Immunology
Peyer’s patches and small intestinal lamina propria were able
to induce FoxP3+ T cells (Figure 3)[ 22–24]. In this regard,
Coombes et al. observed that CD103+ mesenteric lymph
node (MLN) DCs, but not CD103− MLN DCs, were eﬃ-
c i e n ti nc o n v e r s i o no fn a ¨ ıve CD4+ T cells into FoxP3+ T
cells [23]. Consistently, Sun et al. observed that the conver-
sion rate of na¨ ıve T cells into FoxP3+ T cells was high in
intestinal lamina propria and MLN but not PLN [22]. This
conversion was dependent on TGF-β1 as neutralizing anti-
TGF-β1 was able to block the induction while exogenous
TGF-β1 further enhanced the conversion. CD103+ DCs ex-
pressTGF-β2,tissueplasminogenactivator,andTGF-βbind-
ing protein 3 [23]. Tissue plasminogen activator activates la-
tent TGF-β,a n dT G F - β binding protein 3 regulates secretion
andlocalizationofTGF-β[99–101].Anothergroupindepen-
dently reported that CD103+ DCs are CD11b− and induce
IL-10 but fail to induce IL-17 production in T cells [102].
Not only DCs but also some macrophages in the gut can in-
duce FoxP3+ T cells: CD11b+ F4/80+ CD11c− macrophages
express anti-inﬂammatory molecules such as IL-10, TGF-
β1, TGF-β3, program death-ligand 1 (PD-L1 or also called
B7H-1), and PD-L2 (B7-DC), and are eﬃcient in induc-
ing FoxP3+ T cells [102]. The capacity of these antigen-
presenting cells in induction of FoxP3+ T cells is associated
with their ability to produce retinoic acid. Kang et al. showed
that diethylaminobenzaldehyde (DEAB),aninhibitor of reti-
naldehyde dehydrogenases, completely suppressed the in-
duction of FoxP3+ T cells by the mucosal DCs [24]. Mu-
cida et al., Sun et al., and Kang et al. demonstrated that
the mucosal DC-dependent induction of FoxP3+ T cells can
be blocked by RAR antagonists such as LE540, LE135, and
Ro41-5253 [20, 22, 24]. The mucosal DC-dependent induc-
tion of FoxP3+ T cells can be mimicked by activating na¨ ıve
T cells with polyclonal T cell activators in the presence of
retinoic acid and TGF-β1[ 20–26].
FoxP3+ Tcellsofhumansandmicebehavesomewhatdif-
ferently. T cell activation readily upregulate FoxP3 in some
human T cells [103, 104]. In this regard, the human FoxP3
promoter contains six NF-AT and AP-1 binding sites [104].
These molecules act as the major transcription factors that
are activated downstream of TCR activation. However, the
expression levels of FoxP3 in the activated T cells are rel-
atively low and transient [105], and these activated T cells
cannot suppress the proliferation of target T cells. Enforced
expressionofFoxP3inhumanTcellsresultedininductionof
hyporesponsiveness and suppression of IL-2 production but
failed to turn the T cells into T regulatory cells that can sup-
p r e s st a r g e tTc e l l s[ 106], suggesting that additional signals
are required to diﬀerentiate the FoxP3-expressing cells into
fullyfunctionalFoxP3+ Tregulatorycells.Incontrast,simple
activation of mouse FoxP3− T cells in the absence of T reg-
ulatory cell-inducing factors such as TGF-β1d o e sn o tr e a d -
ily generate FoxP3-expressing T cells [20–26], implying that
the expression of FoxP3 is more tightly regulated in mouse
T cells. Contrary to human T cells, enforced expression of
FoxP3 in mouse T cells was suﬃcient to turn FoxP3− Tc e l l s
into functional T regulatory cells which can suppress target
cells [107, 108]. There is another diﬀerence between mouse
and human T cells. Retinoic acid alone is suﬃcient to con-
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Figure 3: Induction and homing of retinoid-induced FoxP3+ T cells.
Gut homing FoxP3+ T cells are made in gut-associated lymphoid
tissues (GALT) but not in the thymus. FoxP3+ T cells made in the
thymus have the na¨ ıve T cell phenotype in expression of homing
receptors and migrate to secondary lymphoid tissues. In the pres-
ence of retinoic acid, these na¨ ıve FoxP3+ T cells become gut homing
memory FoxP3+ T cells. Also, na¨ ıve FoxP3− Tc e l l sb e c o m eF o x P 3 +
T cells in the GALT to become gut homing FoxP3+ Tc e l l s .T h e s e
FoxP3+ Tc e l l se x p r e s sC C R 9a n dα4β7 among other traﬃcking re-
ceptors and are highly eﬃcient in migration to the small intestine.
The diﬀerentiation of these T cells into gut homing FoxP3+ Tc e l l s
is mediated by subsets of dendritic cells and macrophages because
they can present antigens and produce retinoic acid. Additionally,
theepithelialcellinteractingadhesionmoleculeαEβ7isupregulated
on FoxP3+ T cells if the tissue microenvironments have high levels
of TGF-β1. Intestine is such a tissue site that produces both retinoic
acid and TGF-β1.
vert human na¨ ıve T cells undergoing activation into FoxP3+
T cells [24]. However, the TGF-β1 signal is additionally re-
quired to reliably induce FoxP3 in mouse T cells in vitro
[20–26]. It is possible that human T cells are intrinsically dif-
ferent from mouse T cells in expression of certain genes such
as FoxP3 as discussed above. It is also possible that human
na¨ ıve T cells, but not mouse T cells, would produce TGF-β1
[109] at levels high enough for their conversion into FoxP3+
T cells in response to retinoic acid.
Retinoic acid induces histone acetylation in the human
FoxP3 promoter [24]. This acetylation is thought to open
the FoxP3 promoter for active transcription. It is believed
that retinoic acid decreases the aﬃnity for nuclear receptor
corepressor and recruits histone acetyltransferase coactiva-
tors [110], inducing chromatin decondensation and recruit-
ment of the basal transcription machinery to the FoxP3 pro-
moter (Figure 2).Chang H. Kim 5
In a manner similar to the regular FoxP3+ T cells, IL-2
is required for induction of retinoid-induced FoxP3+ Tc e l l s
[20, 24]. IL-2 at high concentrations can increase the induc-
tion of retinoid-induced human FoxP3+ T cells [111]. IL-2
signaling activates STAT5a and b [112], which in turn are
involved in the expression of FoxP3 [113]. It has been re-
ported that RARα can interact with STAT5a and b and coreg-
ulate gene expression [114]. This implies that IL-2 signaling
and STAT5 are required for the retinoic acid-induced FoxP3
expression and generation of functional T regulatory cells.
This, however, turned out to be not true. Elias et al. reported
thatSTAT5-deﬁcientna¨ ıveTcells,althoughlesseﬃcientthan
wild-type T cells, can still be converted to FoxP3+ Tc e l l si n
response to retinoic acid and TGF-β1[ 26]. Therefore, the
retinoic acid & TGF-β1-induced induction of FoxP3 expres-
sion can be enhanced by the IL-2 signaling pathway but does
not absolutely require the IL-2/STAT5 signaling pathway.
TheTcellsstimulatedbyRApreferentiallyexpressRARα,
and RARα antagonists can completely block the retinoic
acid-induced expression of FoxP3 in human T cells [24, 25].
RARαagonistscanmimicretinoicacidininductionofFoxP3
[24, 25]. Therefore, RARα is considered a central recep-
tor that mediates the function of retinoic acid. In this re-
gard, Schambach et al. overexpressed RAR-α in mouse T
cells by retroviral gene transfer and observed an increase in
the FoxP3+ T cell induction [25]. The speciﬁc role of RARα
is further supported by the information that methoprenic
acid (a pan-RXR agonist) was hardly able to induce human
FoxP3+ T cells [24].
In vivo, repetitive injection of retinoic acid subcutaneous
induced small intestine homing FoxP3+ Tc e l l si np e r i p h e r a l
lymph nodes, which are not, normally, the sites for gener-
ation of these T cells [111]. Also, injection of RAR antago-
nistsdecreasedthefrequenciesofFoxP3+ Tcellsinthemouse
small intestine [20]. Moreover, the expression of RARα itself
is induced in T cells activated by retinoic acid [24], which is
considered a positive feedback mechanism for generation of
retinoid-induced FoxP3+ T cells.
4. REGULATION OF HOMING RECEPTOR
EXPRESSION BY RETINOIDS
It is striking that the retinoid-induced FoxP3+ Tc e l l si n
mice and humans have a highly speciﬁc tissue tropism for
the small intestine. Human retinoid-induced FoxP3+ Tc e l l s
highly express CCR9 and α4β7a n de ﬃciently migrate to-
ward the small intestine chemokine TECK/CCL25 [24]. On
the other hand, loss of CD62L expression on the retinoid-
induced FoxP3+ T cells would decrease their migration into
peripheral lymph nodes [24] but further promote their
migration into the small intestine. The mouse or human
retinoid & TGF-β1-induced FoxP3+ T cells are similar to hu-
man retinoid alone-induced FoxP3+ T cells in high expres-
sion of CCR9 and α4β7[ 24]. Interestingly, CD103 (the al-
pha chain of the integrin αEβ7) is more highly expressed by
the retinoid & TGF-β1-induced FoxP3+ T cells than TGF-
β1 alone-induced FoxP3+ T cells [20, 111]. Another pathway
to generate gut homing FoxP3+ T cells is to antigen-prime
preexisting FoxP3+ T cells in the presence of retinoic acid
(retinoid-conditioned FoxP3+ T cells) [19, 111]. In this case,
no TGF-β1 is required to induce FoxP3+ T cells. Retinoid &
TGF-β1-induced FoxP3+ T cells and retinoid alone-induced
(or conditioned) FoxP3+ T cells would migrate to the small
intestine (Figure 3) but they may localize in diﬀerent lo-
cations within the small intestine due to the diﬀerence in
CD103 expression.
5. EFFECTOR FUNCTIONS OF RETINOID-INDUCED
FoxP3+ T CELLS
One can ask if the retinoid-induced FoxP3+ T cells are really
regulatory T cells in terms of functionality because simple
expression of FoxP3 would not necessarily indicate full mat-
uration into T regulatory cells. In this regard, the retinoid-
induced FoxP3+ T cells, induced by retinoic acid from na¨ ıve
human T cells or by retinoic acid plus TGF-β1f r o mm o u s e
or human T cells, appear to have all of the features of the reg-
ulatory T cells. These retinoid-induced human and mouse
FoxP3+ T cells are hypoproliferative and can suppress the
proliferation of other T cells [21, 23–25]. When injected in
vivo, retinoid-induced FoxP3+ T cells eﬃciently suppressed
na¨ ıve T-cell-induced colitis in recombinase-activating gene-
(RAG-) deﬁcient mice [20, 24]. The eﬃcacy of retinoid &
TGF-β1-treated T cells in suppression of colitis was higher
than TGF-β1 alone-treated T cells [20, 24]. However, it is
unknown if retinoid-induced FoxP3+ Tc e l l sa r em o r ee ﬃ-
cient than TGF-β1 alone-induced FoxP3+ T cells in suppres-
sion of diseases in vivo because it is likely that the retinoid
&T G F - β1-treated T cells contain more FoxP3+ T cells than
TGF-β1alone-treatedTcells.Anotherexplanationisthatthe
retinoic acid-induced FoxP3+ T cells are more stable than
TGF-β1 alone-induced FoxP3+ T cells in vivo even after anti-
genic challenge [20–22]. It has been reported that some hu-
man and mouse FoxP3+ T cells express granzymes and can
kill target cells [115–117]. We observed a diﬀerence in ex-
pression of eﬀector molecules between retinoid-induced hu-
man FoxP3+ T cells and retinoid & TGF-β1-induced hu-
manFoxP3+ Tcells[24].Retinoid-inducedhumanFoxP3+ T
cells express granzymes but the retinoid & TGF-β1-induced
FoxP3+ T cells do not express these cytotoxic molecules be-
cause TGF-β1e ﬀectively suppresses their expression [24].
While the retinoid-induced FoxP3+ T cells have the potential
to kill target cells for immunological tolerance in the intes-
tine, it is unknown if the FoxP3+ T cells, present in the in-
testine of mice and humans, can express granzymes and kill
target cells.
6. REGULATION OF Th17 CELLS BY RETINOIDS
It was believed that Th1 cells were the major T cells to induce
autoimmune diseases [118]. An increasing body of evidence,
however, suggests that Th1 cells (and their cytokine prod-
uctIFN-γ ortranscriptionfactorT-bet)playaprotectiverole
in certain autoimmune diseases such as experimental allergic
encephalomyelitis and collagen-induced arthritis [119–121].
This implies that there are additional cell subsets that would
cause autoimmune diseases, and Th1 cells would suppress
the generation or function of the inﬂammatory cells. Many6 Clinical and Developmental Immunology
groups have reported that blocking of IL-23 or IL-17 pre-
vented the development of autoimmune diseases [122–127].
Now, it is well established that Th17 cells constitute a newly
identiﬁed subset of inﬂammatory T cells [3–5]. Th17 cells
characteristically express IL-17A, IL-17F, IL-21, and IL-22
[128–130]. IL17A and IL-17F play important roles in inﬂam-
mation and host defense by inducing IL-6, GM-CSF, G-CSF,
and chemokines [131–133]. IL-21 promotes the generation
of Th17 cells [134, 135]. Interestingly, IL-22 can play anti-
inﬂammatory roles and induces antimicrobial proteins and
lipopolysaccharide-binding protein [136–139]. It is well es-
tablished that IL-6 and TGF-β1 are the major cytokines that
induce mouse Th17 cells [140, 141]. In this regard, mouse
Th17 cells share TGF-β1w i t hF o x P 3 + T cells as an induc-
tive cytokine. However, TGF-β1 alone or together with IL-6
does not promote the generation of human Th17 cells [142].
Also, there is an IL-6-independent pathway to generate Th17
cells [143]. IL-6-independent generation of Th17 cells is me-
diated, in part, by IL-21 and IL-23 [134, 135, 144]. More-
over, IL-6 induces expression of more IL-21 and IL-23 re-
ceptors on T cells to promote Th17 cell generation [144].
Important transcription factors for generation of Th17 cells
include STAT3 (activated by IL-6 and IL-23), ROR-γt, and
ROR-α[145–148].ROR-γtisanorphannuclearreceptorim-
portant also for survival of CD4+8+ thymocytes and the bi-
ology of lymphoid tissue inducer cells [149–151]. ROR-α is
another related orphan nuclear receptor, which is induced by
TGF-β1 and IL-6 in T cells [148]. Yang et al. demonstrated
that overexpression of ROR-α promoted Th17 diﬀerentia-
tion, while ROR-α deﬁciency suppressed the process. More-
over, ROR-α and ROR-γt, when overexpressed together, syn-
ergistically enhanced Th17 diﬀerentiation [148]. As negative
regulators of Th17 cell generation, IL-27 (a Th1 promoting
cytokine) [152, 153] and IL-2 [154] have been identiﬁed.
Amadi-Obi et al., however, reported that IL-2 can expand
human Th17 cells [155] .I nt h i sr e g a r d ,u s eo fI L - 2i ne x p a n -
sion of human Th17 cells has been reported by others too
[142]. Thus, whether inﬂammatory Th17 cells or suppres-
sive FoxP3+ T cells are generated in the periphery would be
determined by the cytokine milieu determined by IL-2, IL-6,
IL-21, IL-27, TGF-β1, and other Th1/2 cytokines present in
the tissue microenvironment. Additionally, there seems to be
somediﬀerencesininductionofTh17cellsbetweenmiceand
humans.
Antigen-presenting cells would play critical roles in gen-
eration of Th17 cells because these cells can present anti-
gens and produce certain inﬂammatory cytokines that can
induce Th17 cells. In this regard, it was reported that MLN
CD103− DCs produce inﬂammatory cytokines such as TNF-
α, IL-6, IL-12p40, and IL-23p19 upon stimulation with LPS
[23]. While Coombes et al. did not examine if the CD103−
DCs could induce Th17 cells, another group examined the
potentialofmucosaldendriticcellsininductionofTh17cells
[102]. Denning et al. reported that intestinal lamina propria
CD11b+ DCs were able to induce Th17 cells very well, while
CD11b− DCswerenoteﬃcient. CD11b+ DCsdonotexpress
CD103, and thus they are the CD103− DCs that Coombes et
al. described in a separate study [23]. In contrast, CD11b−
DCs highly express CD103 and fail to induce IL-17 but are
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Figure 4: Reciprocal regulation of FoxP3+ T cells and Th17 cells by
retinoic acid. IL-2 and TGF-β1 promote the generation of FoxP3+
Tc e l l sf r o mn a ¨ ıve T cells in the periphery, while IL-6 and TGF-β1
promotethegeneration ofTh17cells,aninﬂammatoryTcellsubset
that produces IL-17A, IL-17F, IL-21, and IL-22 as the major eﬀec-
tor cytokines. IL-2 and the cytokines that promote T cell prolifer-
ation into Th1 or Th2 cells (IL-4, IL-12, IFN-γ, and IL-27) would
suppress the generation of Th17 cells, while the pro-Th17 cell cy-
tokines, IL-6 and IL-21, can suppress the generation of FoxP3+ T
cells. Importantly, retinoic acid suppresses the generation of Th17
cells but promotes the induction of FoxP3+ Tc e l l s .
eﬃcient in induction of the anti-inﬂammatory cytokine IL-
10 and FoxP3+ regulatory T cells [102].
At-RA, 9-cis RA or other RAR agonists have potent sup-
pressive activities on generation of Th17 cells (Figure 4)
[20, 24, 25]. Reciprocally, RAR antagonists can enhance the
generation of Th17 cells. In this regard, Elias et al. reported
that retinoic acid can suppress ROR-γt expression in T cells
[26]. It is paradoxical, however, that Th17 cells are present in
theintestineatveryhighfrequencies(∼10%ofCD4+ Tcells)
in the body [147]. It is likely that the antigen-presenting cells
that induce Th17 cells would not be able to produce retinoic
acid and are diﬀerent from the cells that induce gut hom-
ing FoxP3+ T cells. More studies are required to fully under-
stand the maturation process of Th17 cells in terms of tissue
tropism and eﬀector function. Another concern is that most
groups used retinoic acid at pharmacological concentrations
(∼1 μM) to demonstrate the function of retinoic acid in sup-
pression of Th17 cells in vitro. Thus, the in vivo relevance of
the function of retinoic acid remains unclear.
7. CONCLUSION
Intestineisalargeorganthatbydesignisincontactwithfood
digesta, with commensals, and, sometimes, with pathogens.
Maintaining the balance between immunity (to pathogens)
and tolerance (to food antigens and commensals) is criti-
cal to healthy and functional intestine. The recent literature
[20–26] supports the view that retinoic acid is an impor-
tant signal that deﬁnes the “microenvironmental cue” of the
small intestine. It can be produced by gut epithelial cells andChang H. Kim 7
antigen-presenting cells, and it promotes the generation of a
gut homing subset of FoxP3+ T cells. Since FoxP3+ Tc e l l s
are important for maintaining tolerance in the body, it is
likely that retinoic acid is a major signal that confers im-
munological tolerance to the small intestine. On the other
hand,retinoicacidpositivelyregulatesalsoBcellIgAproduc-
tion and induction of gut homing eﬀector T cells, which play
essential roles in conferring immunity against pathogens.
Thus, we conclude that retinoic acid is a common regula-
tor of both immunity and tolerance in the gut. We still do
not completely understand all of the biological functions of
retinoid-induced FoxP3+ T cells in regulation of immunity
and tolerance. Moreover, the readers should be aware of the
fact that humans and mice are not identical in this regula-
tion. Also the in vivo relevance of these functions and their
impacts on immune responses to pathogens and cancer cells
need to be veriﬁed in physiological settings. It is also impor-
tant to investigate if there are additional tissue-speciﬁc sig-
nals that regulate the generation and migration of FoxP3+
and Th17 cells in the gut.
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